Roche’s TIGIT drug misses last shot at survival endpoint win in Phase 3 lung cancer trial
Roche’s TIGIT drug has failed to clear the final hurdle in a late-stage cancer trial in what’s proving to be a mostly disappointing year for …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
